Rayzebio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Rayzebio Inc (RYZB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Rayzebio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Rayzebio Inc | - | - | - | Yes |
| Competitors combined (79) | ||||
| High-Confidence Competitors (104) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RYZB Stock Performance relative to its Competitors
RYZB Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 5 | Omeros Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Rayzebio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Rayzebio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Rayzebio Inc | 962.34 | - |
| Bristol myers Squibb Company | 128,928.40 | 50,033.00 |
| Regeneron Pharmaceuticals Inc | 96,735.94 | 16,896.20 |
| Madrigal Pharmaceuticals Inc | 13,113.46 | 1,427.94 |
| Nuvalent Inc | 9,751.98 | 4.23 |
| Prometheus Biosciences Inc | 9,488.45 | 4.00 |
| SUBTOTAL | 318,217.17 | 73,570.38 |
Sign in to see all competitors of Rayzebio Inc .
Sources: Rayzebio Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Rayzebio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Rayzebio Inc's Competitors Named by the Company
Competitive relationships identified from Rayzebio Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Corvus Pharmaceuticals, Inc. | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Rayzebio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Rayzebio Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Rayzebio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Rayzebio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Rayzebio Inc | 962 | - | - |
| Bristol myers Squibb Company | 128,928 | 1,539,477 | 284,338 |
| Regeneron Pharmaceuticals Inc | 96,736 | 1,096,444 | 312,615 |
| Madrigal Pharmaceuticals Inc | 13,113 | 1,560,590 | -169,905 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Prometheus Biosciences Inc | 9,488 | 27,937 | -1,052,881 |
| PEERS TOTAL | 317,255 | 1,216,542 | 139,654 |
Rayzebio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 69.43 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | IE 27.07 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Rayzebio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (57.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-15.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Rayzebio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Rayzebio Inc | - | - | - |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Prometheus Biosciences Inc | 7.04 | 23.30 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Rayzebio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Rayzebio Inc | Q3 2023 | - | - |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Prometheus Biosciences Inc | Q1 2023 | -71.8 % | - |
| PEERS TOTAL | +17.5 % | +84.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Rayzebio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Rayzebio Inc | Q3 2023 | - | - |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Prometheus Biosciences Inc | Q1 2023 | - | - |
Rayzebio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Rayzebio Inc | - | - | - |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Prometheus Biosciences Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Rayzebio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Rayzebio Inc | - | - |
| Bristol myers Squibb Company | 13.92 | 2.58 |
| Regeneron Pharmaceuticals Inc | 20.26 | 5.73 |
| Madrigal Pharmaceuticals Inc | - | 9.18 |
| Nuvalent Inc | - | 2,303.80 |
| Prometheus Biosciences Inc | - | 2,375.08 |
| PEERS AVERAGE | 37.68 | 4.33 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.